Eye herpes, most commonly called herpes simplex keratitis, is treated with antiviral medications, and sometimes anti-inflammatory eye drops, depending on which layer of the cornea is affected. Treatment can’t eliminate the virus permanently, but it controls active flare-ups and helps prevent the corneal scarring that leads to vision loss. The specific approach your eye doctor takes depends entirely on the type of infection you have.
Why the Type of Infection Matters
Herpes simplex can affect three distinct layers of the cornea, and each one requires a different treatment strategy. Getting this distinction right is critical because using the wrong medication, particularly steroid eye drops, at the wrong time can make the infection dramatically worse.
Epithelial keratitis affects the outermost layer of the cornea. This is the most common form, often producing a branching, tree-like ulcer on the surface of the eye. It’s treated with antivirals alone. Steroid eye drops must be avoided at this stage because they suppress the local immune response and can allow the virus to spread across the corneal surface.
Stromal keratitis involves the middle, structural layer of the cornea. This form is driven partly by the body’s own inflammatory response, so it requires both an oral antiviral and a steroid eye drop for at least ten weeks. The steroid calms the inflammation that causes scarring, while the antiviral keeps the virus in check. Your doctor will carefully adjust the balance between these two medications based on whether there’s any ulceration on the surface.
Endothelial keratitis targets the innermost cell layer. Like stromal disease, it’s treated with a combination of oral antivirals and steroid eye drops. This form can cause corneal swelling and clouding because the endothelial cells are responsible for pumping fluid out of the cornea.
Antiviral Medications
Antivirals are the backbone of every eye herpes treatment plan. They come in two forms: topical (eye drops or ointments applied directly to the eye) and oral (pills you swallow). For surface infections, topical antivirals like ganciclovir gel or trifluridine drops are often the first choice. They work by blocking the virus from copying itself inside corneal cells.
For deeper infections, or when long-term prevention is the goal, oral antivirals are preferred. The most commonly prescribed options are acyclovir, valacyclovir, and famciclovir. These medications reach the eye through the bloodstream and are generally well tolerated, though they need to be taken consistently for the full course your doctor prescribes.
Surface-level infections typically begin to heal within one to two weeks on antiviral therapy. Deeper stromal or endothelial infections take significantly longer, often requiring at least ten weeks of combined treatment before the inflammation is fully controlled. Some people need several months of therapy, and tapering off steroid drops too quickly can trigger a rebound flare.
The Role of Steroid Eye Drops
Steroid eye drops are powerful anti-inflammatory tools, but they’re a double-edged sword in eye herpes. Used correctly for stromal or endothelial disease, they prevent the immune-driven inflammation that scars the cornea and clouds vision. Used incorrectly, during an active surface infection, they can cause the virus to replicate aggressively and create a much larger ulcer.
This is why self-treating eye herpes with leftover steroid drops is dangerous. Even patients who have had previous episodes and recognize the symptoms need an eye exam to confirm which layer is involved before steroids enter the picture. In rare cases where a surface infection and deeper inflammation occur at the same time, a doctor may cautiously use both antivirals and steroids together, but the general rule is to avoid or minimize steroids whenever the surface layer is actively infected.
Debridement for Surface Ulcers
For epithelial keratitis, your eye doctor may perform a quick in-office procedure called debridement before starting antiviral drops. Using a cotton-tipped swab or a small surgical instrument under a slit-lamp microscope, the doctor gently removes the cluster of infected cells from the corneal surface. This reduces the amount of active virus on the eye and allows the antiviral medication to work more effectively on a smaller area of infection. The procedure takes only a few minutes, and the eye heals over the debrided area within a few days.
Preventing Recurrences
Eye herpes has a high recurrence rate. Roughly 1 in 4 people experience another episode within the first year after an initial outbreak. Over longer periods, the numbers climb substantially: about 40% of people have a recurrence within five years, and roughly two-thirds within ten years. Each recurrence carries a risk of additional corneal scarring, so prevention is a major part of long-term management.
For people who have had multiple episodes, or whose first episode caused significant corneal damage, doctors often recommend daily suppressive antiviral therapy. A landmark clinical trial called the Herpetic Eye Disease Study demonstrated that taking a low-dose oral antiviral daily for at least one year significantly reduces the chance of another flare-up. The optimal duration beyond one year isn’t firmly established, and many patients stay on suppressive therapy for years if they tolerate it well.
Anyone with a history of eye herpes who needs eye surgery should be aware that the procedure itself can trigger reactivation. The physical trauma of surgery combined with the steroid drops routinely prescribed afterward creates ideal conditions for the virus to reactivate. Preventive antiviral therapy is strongly recommended in the period surrounding any eye surgery for these patients.
Known Triggers for Flare-Ups
Identifying what triggers reactivation has proven surprisingly difficult. A well-designed prospective study from the Herpetic Eye Disease Study group found no statistically significant link between psychological stress, systemic illness, sunlight exposure, menstrual periods, contact lens wear, or eye injury and recurrence risk. When researchers looked more closely, they discovered that patients who filled out their symptom logs after an outbreak had already started tended to overreport stress and illness in the preceding days, a classic example of recall bias. In other words, people naturally look for a reason after a flare-up and attribute it to whatever felt stressful that week.
That said, some triggers do have biological plausibility. Ultraviolet light exposure is thought to suppress local immune defenses in the eye and has been linked to viral reactivation in laboratory studies. Contact lens wearers appear to have a modestly higher recurrence rate, roughly double that of non-wearers (about 0.4 episodes per year compared to 0.2). And any procedure that traumatizes the cornea, including refractive surgery and corneal crosslinking, can trigger reactivation even in patients who have never had a recognized eye herpes episode before.
When Scarring Threatens Vision
Most people with eye herpes retain good vision, especially if the infection is caught and treated early. The real danger comes from repeated episodes of stromal keratitis, where each round of inflammation can leave behind a bit more scar tissue in the cornea. Over time, this scarring can become dense enough to block light from reaching the retina clearly.
If scarring becomes severe, a corneal transplant may be considered. This involves replacing the damaged cornea with donor tissue. However, the herpes virus remains dormant in the nerve tissue and can reactivate in the transplanted cornea, so patients typically continue suppressive antiviral therapy indefinitely after transplant surgery. The combination of preventive antivirals and careful steroid management gives transplant patients the best chance of keeping the new cornea clear.